pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchison Medi Pharma
Hutchmed Europe B.V.
Hutchison Medi Pharma clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 6
- Programs
- 4
- Drugs
- 6
- Patents
- 0
Hutchison Medi Pharma projects
4 ClinicalTrials.gov programs sponsored by Hutchison Medi Pharma.
Hutchison Medi Pharma has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2018-523-00US1
Hutchmed Europe B.V.
Lymphoma
1 trial -
2020-306-GLOB1
Hutchmed Europe B.V.
- Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)
1 trial -
2022-523-GLOB1
Hutchmed Europe B.V.
Primary immune thrombocytopenia (ITP)
1 trial -
A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations
Hutchmed Europe B.V.
- Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation
1 trial
Frequently asked questions
How many clinical projects does Hutchison Medi Pharma have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.